載入中
NASDAQHealthcareBiotechnology
最新資料
US$26.58
+US$2.09 · +8.53%
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
前收盤價
US$26.58
+US$2.09 · +8.53%
盤中時間採用ET。市場資料可能有所延遲。
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
日內區間
目前US$26.58
52週區間
目前US$26.58
盤中時間採用ET。市場資料可能有所延遲。
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
日內區間
目前US$26.58
52週區間
目前US$26.58
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.76億 USD | 1.97億 USD | 5960.6萬 USD | 368.6萬 USD | — |
| 銷貨成本 | 3669.5萬 USD | 1912.8萬 USD | 498.7萬 USD | 75.4萬 USD | 76.3萬 USD |
| 毛利 | 3.39億 USD | 1.77億 USD | 5461.9萬 USD | 293.2萬 USD | −76.3萬 USD |
| 研究與開發 | 7705.1萬 USD | 7642萬 USD | 1.11億 USD | 1.82億 USD | 1.46億 USD |
| 銷售、一般及管理費用 | 2.75億 USD | 2.29億 USD | 1.85億 USD | 1.22億 USD | 6097.1萬 USD |
| 營業費用 | 3.52億 USD | 3.06億 USD | 2.96億 USD | 3.05億 USD | 2.06億 USD |
| 利息收入 | — | — | — | — | 17.3萬 USD |
| 利息支出 | 1208.3萬 USD | 2716.8萬 USD | 2971.2萬 USD | 1565.2萬 USD | — |
| 折舊和攤銷 | 466.7萬 USD | 259.9萬 USD | 75萬 USD | 93.4萬 USD | 45.4萬 USD |
| 營業利益 | −1222.7萬 USD | −1.28億 USD | −2.41億 USD | −3.02億 USD | −2.07億 USD |
| 淨利 | −1614.1萬 USD | −1.4億 USD | −2.62億 USD | −3.11億 USD | −2.06億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$38.33
上漲空間 44.21%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI8568.37萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI7496.49萬0.76%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM7368.58萬0.09%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF3171.97萬0.03%954億 USD0.05%US$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2589.61萬0.16%158.4億 USD0.03%US$53.45+0.17%
iShares Russell 2000 Growth ETFIWO2588.38萬0.19%139.17億 USD0.24%US$356.78+0.94%
Simplify Health Care ETFPINK2106.7萬6.60%3.19億 USD0.51%US$38.527+2.57%
iShares Biotechnology ETFIBB2076.68萬0.20%108.2億 USD0.44%US$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOSimplify Health Care ETFPINKiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
